News Releases
View printer-friendly version < < backNet earnings and diluted earnings per share for the fourth quarter of 2011 were
Net earnings and diluted earnings per share for the full-year 2011 were
The Company announced earnings guidance for full-year 2012 of
"We delivered solid results for 2011, built on the strong growth of our recently launched pharmaceutical products, and continued the steady momentum of new product approvals across all our businesses," said
Worldwide Consumer sales of
Sales in U.S. over-the-counter medicines were significantly impacted by the suspension of manufacturing at the
Worldwide Pharmaceutical sales of
Sales results in the U.S. were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections, which was offset by the strong performance of recently launched products.
The strong performance of recently launched products include STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone or prednisolone, for the treatment of men with metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA® (paliperidone palmitate) a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; and SIMPONI®(golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Also contributing to operational sales growth were strong results for REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases, including incremental sales from the amended distribution agreement with Merck; recently acquired vaccines, proteins and antibodies from
During the quarter, the
Also during the quarter, supplemental New Drug Applications were submitted to the
Worldwide Medical Devices and Diagnostics sales of
Primary contributors to operational growth included
During the quarter, the
About
Caring for the world, one person at a time…inspires and unites the people of
* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.
NOTE TO INVESTORS
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care
cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Supplementary Sales Data |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars in Millions) |
|
FOURTH QUARTER |
|
TWELVE MONTHS | ||||||||||||||||
|
|
|
|
|
|
|
Percent Change |
|
|
|
|
|
|
|
|
Percent Change |
|
| ||
|
2011 |
|
|
2010 |
|
Total |
|
Operations |
|
Currency |
|
2011 |
|
2010 |
|
Total |
|
Operations |
|
Currency |
Sales to customers by |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of business |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. |
$ 1,248 |
|
|
1,219 |
|
2.4 |
% |
2.4 |
|
- |
|
$ 5,151 |
|
5,519 |
|
(6.7) |
% |
(6.7) |
|
- |
International |
2,420 |
|
|
2,391 |
|
1.2 |
|
2.8 |
|
(1.6) |
|
9,732 |
|
9,071 |
|
7.3 |
|
2.9 |
|
4.4 |
|
3,668 |
|
|
3,610 |
|
1.6 |
|
2.7 |
|
(1.1) |
|
14,883 |
|
14,590 |
|
2.0 |
|
(0.7) |
|
2.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. |
2,887 |
|
|
3,149 |
|
(8.3) |
|
(8.3) |
|
- |
|
12,386 |
|
12,519 |
|
(1.1) |
|
(1.1) |
|
- |
International |
3,207 |
|
|
2,561 |
|
25.2 |
|
25.0 |
|
0.2 |
|
11,982 |
|
9,877 |
|
21.3 |
|
15.5 |
|
5.8 |
|
6,094 |
|
|
5,710 |
|
6.7 |
|
6.6 |
|
0.1 |
|
24,368 |
|
22,396 |
|
8.8 |
|
6.2 |
|
2.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Med Devices & Diagnostics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. |
2,850 |
|
|
2,861 |
|
(0.4) |
|
(0.4) |
|
- |
|
11,371 |
|
11,412 |
|
(0.4) |
|
(0.4) |
|
- |
International |
3,643 |
|
|
3,463 |
|
5.2 |
|
4.6 |
|
0.6 |
|
14,408 |
|
13,189 |
|
9.2 |
|
3.4 |
|
5.8 |
|
6,493 |
|
|
6,324 |
|
2.7 |
|
2.4 |
|
0.3 |
|
25,779 |
|
24,601 |
|
4.8 |
|
1.7 |
|
3.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. |
6,985 |
|
|
7,229 |
|
(3.4) |
|
(3.4) |
|
- |
|
28,908 |
|
29,450 |
|
(1.8) |
|
(1.8) |
|
- |
International |
9,270 |
|
|
8,415 |
|
10.2 |
|
10.4 |
|
(0.2) |
|
36,122 |
|
32,137 |
|
12.4 |
|
7.0 |
|
5.4 |
Worldwide |
$ 16,255 |
|
|
15,644 |
|
3.9 |
% |
4.0 |
|
(0.1) |
|
$ 65,030 |
|
61,587 |
|
5.6 |
% |
2.8 |
|
2.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Supplementary Sales Data |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars in Millions) |
FOURTH QUARTER |
|
TWELVE MONTHS | ||||||||||||||||
|
|
|
|
|
|
Percent Change |
|
|
|
|
|
|
|
|
Percent Change |
|
| ||
|
2011 |
|
2010 |
|
Total |
|
Operations |
|
Currency |
|
2011 |
|
2010 |
|
Total |
|
Operations |
|
Currency |
Sales to customers by |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic area |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. |
$ 6,985 |
|
7,229 |
|
(3.4) |
% |
(3.4) |
|
- |
|
$ 28,908 |
|
29,450 |
|
(1.8) |
% |
(1.8) |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,279 |
|
3,947 |
|
8.4 |
|
9.4 |
|
(1.0) |
|
17,129 |
|
15,510 |
|
10.4 |
|
5.3 |
|
5.1 |
Western Hemisphere excluding U.S. |
1,688 |
|
1,471 |
|
14.8 |
|
17.8 |
|
(3.0) |
|
6,418 |
|
5,550 |
|
15.6 |
|
12.2 |
|
3.4 |
|
3,303 |
|
2,997 |
|
10.2 |
|
7.9 |
|
2.3 |
|
12,575 |
|
11,077 |
|
13.5 |
|
6.6 |
|
6.9 |
International |
9,270 |
|
8,415 |
|
10.2 |
|
10.4 |
|
(0.2) |
|
36,122 |
|
32,137 |
|
12.4 |
|
7.0 |
|
5.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide |
$ 16,255 |
|
15,644 |
|
3.9 |
% |
4.0 |
|
(0.1) |
|
$ 65,030 |
|
61,587 |
|
5.6 |
% |
2.8 |
|
2.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statement of Earnings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in Millions Except Per Share Figures) |
FOURTH QUARTER | ||||||||
|
|
|
|
|
|
|
|
|
|
|
2011 |
|
2010 |
|
Percent | ||||
|
|
|
Percent |
|
|
|
Percent |
|
Increase |
|
Amount |
|
to Sales |
|
Amount |
|
to Sales |
|
(Decrease) |
Sales to customers |
|
|
100.0 |
|
|
|
100.0 |
|
3.9 |
Cost of products sold |
5,338 |
|
32.8 |
|
5,040 |
|
32.2 |
|
5.9 |
Selling, marketing and administrative expenses |
5,458 |
|
33.6 |
|
5,180 |
|
33.1 |
|
5.4 |
Research and development expense |
2,155 |
|
13.3 |
|
1,982 |
|
12.7 |
|
8.7 |
Interest (income)expense, net |
148 |
|
0.9 |
|
114 |
|
0.7 |
|
|
Other (income)expense, net |
2,858 |
|
17.6 |
|
1,100 |
|
7.1 |
|
|
Restructuring (income)expense, net |
(20) |
|
(0.1) |
|
- |
|
- |
|
|
Earnings before provision for taxes on income |
318 |
|
1.9 |
|
2,228 |
|
14.2 |
|
(85.7) |
Provision for taxes on income |
100 |
|
0.6 |
|
286 |
|
1.8 |
|
(65.0) |
Net earnings |
$ 218 |
|
1.3 |
|
$ 1,942 |
|
12.4 |
|
(88.8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings per share (Diluted) |
$ 0.08 |
|
|
|
$ 0.70 |
|
|
|
(88.6) |
|
|
|
|
|
|
|
|
|
|
Average shares outstanding (Diluted) |
2,768.9 |
|
|
|
2,781.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax rate |
31.4 |
% |
|
|
12.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings before provision for taxes and net earnings |
|
|
|
|
|
|
|
|
|
Earnings before provision for taxes on income |
$ 3,657 |
(1) |
22.5 |
|
$ 3,451 |
(1) |
22.1 |
|
6.0 |
Net earnings |
$ 3,129 |
(1) |
19.2 |
|
$ 2,864 |
(1) |
18.3 |
|
9.3 |
Net earnings per share (Diluted) |
$ 1.13 |
(1) |
|
|
$ 1.03 |
(1) |
|
|
9.7 |
Effective tax rate |
14.4% |
|
|
|
17.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statement of Earnings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in Millions Except Per Share Figures) |
TWELVE MONTHS | ||||||||
|
|
|
|
|
|
|
|
|
|
|
2011 |
|
2010 |
|
Percent | ||||
|
|
|
Percent |
|
|
|
Percent |
|
Increase |
|
Amount |
|
to Sales |
|
Amount |
|
to Sales |
|
(Decrease) |
Sales to customers |
|
|
100.0 |
|
|
|
100.0 |
|
5.6 |
Cost of products sold |
20,360 |
|
31.3 |
|
18,792 |
|
30.5 |
|
8.3 |
Selling, marketing and administrative expenses |
20,969 |
|
32.3 |
|
19,424 |
|
31.5 |
|
8.0 |
Research and development expense |
7,548 |
|
11.6 |
|
6,844 |
|
11.1 |
|
10.3 |
Interest (income)expense, net |
480 |
|
0.7 |
|
348 |
|
0.6 |
|
|
Other (income)expense, net |
2,743 |
|
4.2 |
|
(768) |
|
(1.2) |
|
|
Restructuring (income)expense, net |
569 |
|
0.9 |
|
- |
|
- |
|
|
Earnings before provision for taxes on income |
12,361 |
|
19.0 |
|
16,947 |
|
27.5 |
|
(27.1) |
Provision for taxes on income |
2,689 |
|
4.1 |
|
3,613 |
|
5.8 |
|
(25.6) |
Net earnings |
$ 9,672 |
|
14.9 |
|
|
|
21.7 |
|
(27.5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings per share (Diluted) |
$ 3.49 |
|
|
|
$ 4.78 |
|
|
|
(27.0) |
|
|
|
|
|
|
|
|
|
|
Average shares outstanding (Diluted) |
2,775.3 |
|
|
|
2,788.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax rate |
21.8 |
% |
|
|
21.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings before provision for taxes and net earnings |
|
|
|
|
|
|
|
|
|
Earnings before provision for taxes on income |
|
(1) |
26.7 |
|
|
(1) |
27.3 |
|
3.1 |
Net earnings |
|
(1) |
21.3 |
|
|
(1) |
21.6 |
|
4.4 |
Net earnings per share (Diluted) |
$ 5.00 |
(1) |
|
|
$ 4.76 |
(1) |
|
|
5.0 |
Effective tax rate |
20.1% |
|
|
|
21.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|
|
REPORTED SALES vs. PRIOR PERIOD ($MM) |
| |||||||
|
FOURTH QUARTER |
|
TWELVE MONTHS | ||||||||
|
|
|
% Change |
|
|
|
% Change | ||||
|
2011 |
2010 |
Reported |
Operational (1) |
Currency |
|
2011 |
2010 |
Reported |
Operational (1) |
Currency |
CONSUMER SEGMENT (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US |
103 |
103 |
0.0% |
0.0% |
- |
|
418 |
409 |
2.2% |
2.2% |
- |
|
465 |
474 |
-1.9% |
0.7% |
-2.6% |
|
1,922 |
1,800 |
6.8% |
3.4% |
3.4% |
WW |
568 |
577 |
-1.6% |
0.6% |
-2.2% |
|
2,340 |
2,209 |
5.9% |
3.2% |
2.7% |
ORAL CARE |
|
|
|
|
|
|
|
|
|
|
|
US |
173 |
149 |
16.1% |
16.1% |
- |
|
656 |
635 |
3.3% |
3.3% |
- |
|
239 |
240 |
-0.4% |
1.4% |
-1.8% |
|
968 |
891 |
8.6% |
3.9% |
4.7% |
WW |
412 |
389 |
5.9% |
7.0% |
-1.1% |
|
1,624 |
1,526 |
6.4% |
3.6% |
2.8% |
OTC/NUTRITIONALS |
|
|
|
|
|
|
|
|
|
|
|
US |
370 |
381 |
-2.9% |
-2.9% |
- |
|
1,429 |
1,853 |
-22.9% |
-22.9% |
- |
|
766 |
711 |
7.7% |
8.7% |
-1.0% |
|
2,973 |
2,696 |
10.3% |
5.2% |
5.1% |
WW |
1,136 |
1,092 |
4.0% |
4.6% |
-0.6% |
|
4,402 |
4,549 |
-3.2% |
-6.2% |
3.0% |
|
|
|
|
|
|
|
|
|
|
|
|
US |
403 |
352 |
14.5% |
14.5% |
- |
|
1,654 |
1,537 |
7.6% |
7.6% |
- |
|
541 |
537 |
0.7% |
1.3% |
-0.6% |
|
2,061 |
1,915 |
7.6% |
3.0% |
4.6% |
WW |
944 |
889 |
6.2% |
6.6% |
-0.4% |
|
3,715 |
3,452 |
7.6% |
5.0% |
2.6% |
WOMEN'S HEALTH |
|
|
|
|
|
|
|
|
|
|
|
US |
89 |
118 |
-24.6% |
-24.6% |
- |
|
439 |
522 |
-15.9% |
-15.9% |
- |
|
309 |
332 |
-6.9% |
-4.0% |
-2.9% |
|
1,353 |
1,322 |
2.3% |
-1.5% |
3.8% |
WW |
398 |
450 |
-11.6% |
-9.5% |
-2.1% |
|
1,792 |
1,844 |
-2.8% |
-5.5% |
2.7% |
WOUND CARE/OTHER |
|
|
|
|
|
|
|
|
|
|
|
US |
110 |
116 |
-5.2% |
-5.2% |
- |
|
555 |
563 |
-1.4% |
-1.4% |
- |
|
100 |
97 |
3.1% |
6.2% |
-3.1% |
|
455 |
447 |
1.8% |
-3.3% |
5.1% |
WW |
210 |
213 |
-1.4% |
-0.5% |
-0.9% |
|
1,010 |
1,010 |
0.0% |
-2.3% |
2.3% |
TOTAL CONSUMER |
|
|
|
|
|
|
|
|
|
|
|
US |
1,248 |
1,219 |
2.4% |
2.4% |
- |
|
5,151 |
5,519 |
-6.7% |
-6.7% |
- |
|
2,420 |
2,391 |
1.2% |
2.8% |
-1.6% |
|
9,732 |
9,071 |
7.3% |
2.9% |
4.4% |
WW |
3,668 |
3,610 |
1.6% |
2.7% |
-1.1% |
|
14,883 |
14,590 |
2.0% |
-0.7% |
2.7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end of schedule |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs. PRIOR PERIOD ($MM) |
| ||||||||
|
FOURTH QUARTER |
|
TWELVE MONTHS | ||||||||
|
|
|
% Change |
|
|
|
% Change | ||||
|
2011 |
2010 |
Reported |
Operational (1) |
Currency |
|
2011 |
2010 |
Reported |
Operational (1) |
Currency |
PHARMACEUTICAL SEGMENT (2) (4) |
|
|
|
|
|
|
|
|
|
|
|
ACIPHEX/PARIET |
|
|
|
|
|
|
|
|
|
|
|
US |
110 |
119 |
-7.6% |
-7.6% |
- |
|
414 |
475 |
-12.8% |
-12.8% |
- |
|
144 |
133 |
8.3% |
8.7% |
-0.4% |
|
561 |
531 |
5.6% |
0.0% |
5.6% |
WW |
254 |
252 |
0.8% |
1.0% |
-0.2% |
|
975 |
1,006 |
-3.1% |
-6.1% |
3.0% |
CONCERTA/METHYLPHENIDATE |
|
|
|
|
|
|
|
|
|
|
|
US |
155 |
261 |
-40.6% |
-40.6% |
- |
|
822 |
929 |
-11.5% |
-11.5% |
- |
|
119 |
107 |
11.2% |
11.6% |
-0.4% |
|
446 |
390 |
14.4% |
8.7% |
5.7% |
WW |
274 |
368 |
-25.5% |
-25.4% |
-0.1% |
|
1,268 |
1,319 |
-3.9% |
-5.6% |
1.7% |
DOXIL/CAELYX |
|
|
|
|
|
|
|
|
|
|
|
US |
10 |
55 |
-81.8% |
-81.8% |
- |
|
140 |
280 |
-50.0% |
-50.0% |
- |
|
29 |
12 |
* |
* |
-10.3% |
|
262 |
40 |
* |
* |
5.3% |
WW |
39 |
67 |
-41.8% |
-34.1% |
-7.7% |
|
402 |
320 |
25.6% |
22.1% |
3.5% |
DURAGESIC/FENTANYL TRANSDERMAL |
|
|
|
|
|
|
|
|
|
|
|
US |
21 |
45 |
-53.3% |
-53.3% |
- |
|
90 |
162 |
-44.4% |
-44.4% |
- |
|
119 |
151 |
-21.2% |
-21.9% |
0.7% |
|
499 |
586 |
-14.8% |
-20.1% |
5.3% |
WW |
140 |
196 |
-28.6% |
-29.1% |
0.5% |
|
589 |
748 |
-21.3% |
-25.5% |
4.2% |
LEVAQUIN/FLOXIN |
|
|
|
|
|
|
|
|
|
|
|
US |
(6) |
386 |
* |
* |
- |
|
579 |
1,312 |
-55.9% |
-55.9% |
- |
|
11 |
14 |
-21.4% |
-17.7% |
-3.7% |
|
44 |
45 |
-2.2% |
-3.7% |
1.5% |
WW |
5 |
400 |
-98.8% |
-98.7% |
-0.1% |
|
623 |
1,357 |
-54.1% |
-54.2% |
0.1% |
PREZISTA |
|
|
|
|
|
|
|
|
|
|
|
US |
143 |
111 |
28.8% |
28.8% |
- |
|
529 |
401 |
31.9% |
31.9% |
- |
|
173 |
125 |
38.4% |
39.0% |
-0.6% |
|
682 |
456 |
49.6% |
44.8% |
4.8% |
WW |
316 |
236 |
33.9% |
34.2% |
-0.3% |
|
1,211 |
857 |
41.3% |
38.6% |
2.7% |
PROCRIT/EPREX |
|
|
|
|
|
|
|
|
|
|
|
US |
191 |
270 |
-29.3% |
-29.3% |
- |
|
814 |
1,070 |
-23.9% |
-23.9% |
- |
|
177 |
209 |
-15.3% |
-13.7% |
-1.6% |
|
809 |
864 |
-6.4% |
-10.8% |
4.4% |
WW |
368 |
479 |
-23.2% |
-22.6% |
-0.6% |
|
1,623 |
1,934 |
-16.1% |
-18.0% |
1.9% |
REMICADE |
|
|
|
|
|
|
|
|
|
|
|
US |
776 |
679 |
14.3% |
14.3% |
- |
|
3,276 |
3,099 |
5.7% |
5.7% |
- |
US Exports (3) |
437 |
381 |
14.7% |
14.7% |
- |
|
1,797 |
1,487 |
20.8% |
20.8% |
- |
|
215 |
5 |
* |
* |
2.3% |
|
419 |
24 |
* |
* |
4.8% |
WW |
1,428 |
1,065 |
34.1% |
33.6% |
0.5% |
|
5,492 |
4,610 |
19.1% |
18.7% |
0.4% |
RISPERDAL/RISPERIDONE |
|
|
|
|
|
|
|
|
|
|
|
US |
7 |
2 |
* |
* |
- |
|
34 |
(12) |
* |
* |
- |
|
141 |
149 |
-5.4% |
-7.9% |
2.5% |
|
508 |
539 |
-5.8% |
-11.6% |
5.8% |
WW |
148 |
151 |
-2.0% |
-4.4% |
2.4% |
|
542 |
527 |
2.8% |
-3.1% |
5.9% |
RISPERDAL CONSTA |
|
|
|
|
|
|
|
|
|
|
|
US |
108 |
105 |
2.9% |
2.9% |
- |
|
443 |
445 |
-0.4% |
-0.4% |
- |
|
277 |
283 |
-2.1% |
-1.3% |
-0.8% |
|
1,140 |
1,055 |
8.1% |
2.7% |
5.4% |
WW |
385 |
388 |
-0.8% |
-0.2% |
-0.6% |
|
1,583 |
1,500 |
5.5% |
1.7% |
3.8% |
TOPAMAX |
|
|
|
|
|
|
|
|
|
|
|
US |
40 |
37 |
8.1% |
8.1% |
- |
|
176 |
199 |
-11.6% |
-11.6% |
- |
|
81 |
84 |
-3.6% |
-2.6% |
-1.0% |
|
312 |
339 |
-8.0% |
-11.9% |
3.9% |
WW |
121 |
121 |
0.0% |
0.7% |
-0.7% |
|
488 |
538 |
-9.3% |
-11.8% |
2.5% |
VELCADE |
|
|
|
|
|
|
|
|
|
|
|
US |
- |
- |
- |
- |
- |
|
- |
- |
- |
- |
- |
|
352 |
287 |
22.6% |
22.4% |
0.2% |
|
1,274 |
1,080 |
18.0% |
12.7% |
5.3% |
WW |
352 |
287 |
22.6% |
22.4% |
0.2% |
|
1,274 |
1,080 |
18.0% |
12.7% |
5.3% |
OTHER |
|
|
|
|
|
|
|
|
|
|
|
US |
895 |
698 |
28.2% |
28.2% |
- |
|
3,272 |
2,672 |
22.5% |
22.5% |
- |
|
1,369 |
1,002 |
36.6% |
36.0% |
0.6% |
|
5,026 |
3,928 |
28.0% |
22.2% |
5.8% |
WW |
2,264 |
1,700 |
33.2% |
32.8% |
0.4% |
|
8,298 |
6,600 |
25.7% |
22.2% |
3.5% |
TOTAL PHARMACEUTICAL |
|
|
|
|
|
|
|
|
|
|
|
US |
2,887 |
3,149 |
-8.3% |
-8.3% |
- |
|
12,386 |
12,519 |
-1.1% |
-1.1% |
- |
|
3,207 |
2,561 |
25.2% |
25.0% |
0.2% |
|
11,982 |
9,877 |
21.3% |
15.5% |
5.8% |
WW |
6,094 |
5,710 |
6.7% |
6.6% |
0.1% |
|
24,368 |
22,396 |
8.8% |
6.2% |
2.6% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end of schedule |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
FOURTH QUARTER |
|
|
|
TWELVE MONTHS |
|
| ||||
|
|
|
Total |
|
|
|
|
|
Total |
|
|
MAJOR NEW PHARM PRODUCTS(4) |
2011 |
2010 |
% Change |
|
|
|
2011 |
2010 |
% Change |
|
|
(INCLUDED IN OTHER) |
|
|
|
|
|
|
|
|
|
|
|
INTELENCE |
|
|
|
|
|
|
|
|
|
|
|
US |
45 |
34 |
32.4% |
|
|
|
163 |
127 |
28.3% |
|
|
|
38 |
31 |
22.6% |
|
|
|
151 |
116 |
30.2% |
|
|
WW |
83 |
65 |
27.7% |
|
|
|
314 |
243 |
29.2% |
|
|
INVEGA |
|
|
|
|
|
|
|
|
|
|
|
US |
66 |
70 |
-5.7% |
|
|
|
285 |
270 |
5.6% |
|
|
|
59 |
46 |
28.3% |
|
|
|
214 |
154 |
39.0% |
|
|
WW |
125 |
116 |
7.8% |
|
|
|
499 |
424 |
17.7% |
|
|
SIMPONI |
|
|
|
|
|
|
|
|
|
|
|
US |
62 |
56 |
10.7% |
|
|
|
235 |
193 |
21.8% |
|
|
|
57 |
9 |
* |
|
|
|
175 |
33 |
* |
|
|
WW |
119 |
65 |
83.1% |
|
|
|
410 |
226 |
81.4% |
|
|
STELARA |
|
|
|
|
|
|
|
|
|
|
|
US |
126 |
73 |
72.6% |
|
|
|
443 |
240 |
84.6% |
|
|
|
81 |
47 |
72.3% |
|
|
|